Clinical Trial

Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

Study acronym: TreoMel
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Clinical trial investigating the chemotherapeutic compound treosulfan (Trecondi® Ideogen) in myeloma patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-11-23; most recent amendment 2024-07-04.
Status change: Not Yet Recruiting → Recruiting 2023-05-04
Trial Details
NCT Number NCT05636787
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Multiple Myeloma
Enrollment 120 participants
Start Date 2023-06-06
Primary Completion 2028-01 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2024-07-08